Sepsis and Markers of Sepsis - An Update;Sepsis und Sepsismarker - Update

LaboratoriumsMedizin

Volumn 27, Issue 11-12, 2003, Pages 431-439

  Wahl, Hans Günther ^a   Herzum, I ^a   Renz, H ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Cytokines; Immunological monitoring; Marker; Mediator; Sepsis

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PROCALCITONIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE ACTIVATING FACTOR; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR;

HEMODYNAMIC PARAMETERS; HUMAN; HYPOTENSION; HYPOXIA; IMMUNE RESPONSE; INFLAMMATION; LABORATORY DIAGNOSIS; MULTIPLE ORGAN FAILURE; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 0348012996     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/LabMed.2003.060     Document Type: Review

References (62)

1. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001;29:S109-16.
2. Schuster HP, Werdan K. Intensivtherapie bei Sepsis und Multiorganversagen. Springer Verlag Berlin Heidelberg 1999:S17.
3. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003;29:530-8.
4. Llewelyn M, Cohen J. Diagnosis of infection in sepsis. Intensive Care Med 2001;27(Suppl 1):S10-S32.
5. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997;25:372-4.
6. Marshall JC, Vincent JL, Fink MP, et al. Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 2003;31:1560-7.
7. Henderson AR, Bhayana V. A modest proposal for the consistent presentation of ROC plots in Clinical Chemistry. Clin Chem 1995;41:1205-6.
8. Henderson AR. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem 1993;30:521-39.
9. Delgado-Rodriguez M, Almaraz A, Farinas-Alvarez C. Should the definition for the negative likelihood ratio be changed? J Clin Epidemiol 1997;50:641-2.
10. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 2000;45:23-41.
11. Gambino R. The misuse of predictive value-or why you must consider the odds. Ann Ist Super Sanita 1991;27:395-9.
12. Sasse EA. Objective evaluation of data in screening for disease. Clin Chim Acta 2002;315:17-30.
13. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
14. Silva PS, Fonseca MC, Iglesias SB, Carvalho WB, Bussolan RM, Freitas IW. Comparison of two different severity scores (Paediatric Risk of Mortality [PRISM] and the Glasgow Meningococcal Sepsis Prognostic Score [GMSPS]) in meningococcal disease: preliminary analysis. Ann Trop Paediatr 2001;21:135-40.
15. Oda S, Hirasawa H, Sugai T, et al. Comparison of Sepsis-related Organ Failure Assessment (SOFA) score and CIS (cellular injury score) for scoring of severity for patients with multiple organ dysfunction syndrome (MODS). Intensive Care Med 2000;26:1786-93.
16. Bencosme A, Warner A, Healy D, Verme C. Prognostic potential of cytokines, nitrates, and APACHE II score in sepsis. Ann Clin Lab Sci 1996;26:426-32.
17. Michie HR, Spriggs DR, Manogue KR, et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988;104:280-6.
18. Suffredini AF, Fromm RE, Parker MM. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-7.
19. Cohen J, Guyatt G, Bernard GR, et al. New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 2001;29:880-6.
20. Monneret G, Elmenkouri N, Bohe J, et al. Analytical requirements for measuring monocytic human lymphocyte antigen DR by flow cytometry: application to the monitoring of patients with septic shock. Clin Chem 2002;48:1589-92.
21. Nierhaus A, Montag B, Timmler N, et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 2003;29:646-51.
22. Grimminger F, Mayer K, Seeger W. [Is there a reliable immunotherapy in infection?]. Internist 1997;38:541-52.
23. Muller KA, Tulleken JE, Zijlstra JG, et al. Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med 2000;26:883-92.
24. Frauenberger P, Walli AK. Stellenwert von Zytokinen in der Sepsis Diagnostik. Infusionsther Transfusionsmed 1996;23:109-16.
25. Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinhart K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 1999;37:363-8.
26. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003;31:1737-41.
27. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-8.
28. Rau B, Steinbach G, Gansauge F, Mayer JM, Grunert A, Beger HG. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997;41:832-40.
29. Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000;28:977-83.
30. Brunkhorst FM, Eberhard OK, Brunkhorst R. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 1999;27:2172-6.
31. Marik PE. Definition of sepsis: not quite time to dump SIRS? Crit Care Med 2002;30:706-8.
32. Ugarte H, Silva E, Mercan D, de Mendonca A, Vincent JL. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 1999;27:498-504.
33. Shaw AC. Serum C-reactive protein and neopterin concentrations in patients with viral or bacterial infection. J Clin Pathol 1991 44:596-9.
34. Reny JL, Vuagnat A, Ract C, Benoit MO, Safar M, Fagon JY.: Diagnosis and follow-up of infections in intensive care patients: value of C-reactive protein compared with other clinical and biological variables. Crit Care Med 2002;30:529-35.
35. Adnet F, Borron SW, Vicaut E, et al. Value of C-reactive protein in the detection of bacterial contamination at the time of presentation in drug-induced aspiration pneumonia. Chest 1997;112:466-71.
36. Berner R, Niemeyer CM, Leititis JU, et al. Plasma levels and gene expression of granulocyte colony-stimulating factor, tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, IL-8, and soluble intercellular adhesion molecule-1 in neonatal early onset sepsis. Pediatr Res 1998;44:469-77.
37. Santana C, Guindeo MC, Gonzalez G, Garcia-Munoz F, Saavedra P, Domenech E. Cord blood levels of cytokines as predictors of early neonatal sepsis. Acta Paediatr 2001;90:1176-81.
38. Dollner H, Vatten L, Austgulen R. Early diagnostic markers for neonatal sepsis: comparing C-reactive protein, interleukin-6, soluble tumour necrosis factor receptors and soluble adhesion molecules. J Clin Epidemiol 2001;54:1251-7.
39. Martin H, Olander B, Norman M. Reactive hyperemia and interleukin 6, interleukin 8, and tumor necrosis factor-alpha in the diagnosis of early-onset neonatal sepsis. Pediatrics 2001;108:E61
40. Kunz D, Kohse KP. Entzündungsdiagnostik in der Pädiatrie. Pädiatrisches Labor 2002;26:335-40.
41. Spittler, A. Is monocyte HLA-DR expression predictive for clinical outcome in sepsis? Intensive Care Med 2003;8:1211-2.
42. http://www.dgkc.de/org/fraGemAkademie.html: eingesehen am 15.7.2003.
43. Nijsten MW, Olinga P, The TH, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000;28:458-61.
44. Oberhoffer M, Vogelsang H, Jager L, Reinhart K. Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J Crit Care 1999;14:29-33.
45. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79:1605-8.
46. Redl H, Schlag G, Togel E, Assicot M, Bohuon C. Procalcitonin release patterns in a baboon model of trauma and sepsis: relationship to cytokines and neopterin. Crit Care Med 2000;28:3659-63.
47. Nijsten MW, Olinga P. In vitro and in vivo stimulation of procalcitonin by TNFα and IL6. J für Anästh und Intensivtherapie 2001;2:58
48. Whang KT, Vath SD, Becker KL, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock 2000;14:73-8.
49. Chiesa C, Pellegrini G, Panero A, et al. C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem 2003;49:60-8.
50. Assumma M, Signore F, Pacifico L, Rossi N, Osborn JF, Chiesa C. Serum procalcitonin concentrations in term delivering mothers and their healthy offspring: a longitudinal study. Clin Chem 2000;46:1583-7.
51. Suprin E, Camus C, Gacouin A, et al. Procalcitonin: a valuable indicator of infection in a medical ICU? Intensive Care Med 2000;26:1232-8.
52. Mimoz O, Benoist JF, Edouard AR, Assicot M, Bohuon C, Samii K. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med 1998;24:185-8.
53. Swank GM, Deitch EA. Role of the gut in multiple organ failure: bacterial translocation and permeability changes. World J Surg 1996;20:411-7.
54. Nylen ES, Whang KT, Snider RHJ, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998;26:1001-6.
55. Thomas L (Hrsg). Labor und Diagnose. Marburg: Med Verlagsgesellschaft 1998;717.
56. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164 396-402.
57. Thomas L (Hersg). Labor und Diagnose. Marburg: Med Verlagsgesellschaft 1998;788.
58. Mehr S, Doyle LW. Cytokines as markers of bacterial sepsis in newborn infants: a review. Pediatr Infect Dis J 2000;19:879-87.
59. Chiesa C, Signore F, Assumma M, et al. Serial measurements of C-reactive protein and interleukin-6 in the immediate postnatal period: reference intervals and analysis of maternal and perinatal confounders. Clin Chem 2001;47:1016-22.
60. Franz AR, Steinbach G, Kron M, Pohlandt F. Reduction of unnecessary antibiotic therapy in newborn infants using interleukin-8 and C-reactive protein as markers of bacterial infections. Pediatrics 1999;104:447-53.
61. Negussie Y, Remick DG, DeForge LE, Kunkel SL, Eynon A, Griffin GE. Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer Reaction of relapsing fever. J Exp Med 1992;175:1207-12.
62. Santana RC, Garcia-Munoz F, Reyes D, Gonzalez G, Dominguez C, Domenech E. Role of cytokines (interleukin-1beta, 6, 8, tumour necrosis factor-alpha, and soluble receptor of interleukin-2) and C-reactive protein in the diagnosis of neonatal sepsis. Acta Paediatr 2003;92:221-7.